Company Overview and News

7
NCNA / NuCana plc / Wood Christopher B - SC 13G (Passive Investment)

2018-07-13 sec.gov
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
NCNA

7
NCNA / NuCana plc / Wood Christopher B - SC 13G (Passive Investment)

2018-07-13 sec.gov
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
NCNA

16
NCNA / NuCana plc - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-13 fintel.io
NuCana plc (NASDAQ:NCNA) has 22 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 14,753,155 shares. Largest shareholders include Sofinnova Ventures Inc, Sofinnova Management VIII, L.L.C., Capital Research Global Investors, Capital World Investors, Baillie Gifford & Co, Alliancebernstein L.p.
NCNA CATB

7
NCNA / NuCana plc / Griffith Hugh - SC 13G (Passive Investment)

2018-07-13 sec.gov
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
NCNA

7
NCNA / NuCana plc / Griffith Hugh - SC 13G (Passive Investment)

2018-07-13 sec.gov
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
NCNA

6
NCNA / NuCana plc FORM 6-K (Current Report of Foreign Issuer)

2018-06-29 sec.gov - 6
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
NCNA

24
A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

2018-06-16 seekingalpha - 1
Without positive cash flows to analyze (and no promise of ever achieving a marketed product), cancer stocks are very tough to gauge fundamentally.
NCNA VBLT VBLTF

3
NCNA / NuCana plc FORM 6-K (Current Report of Foreign Issuer)

2018-06-01 sec.gov - 3
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
NCNA

0
NCNA / NuCana plc FORM 6-K (Current Report of Foreign Issuer)

2018-05-28 sec.gov
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
NCNA

4
NCNA / NuCana plc 6-K (Current Report of Foreign Issuer)

2018-05-21 sec.gov - 4
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
NCNA

0
NuCana CEO Hugh Griffith Honored with the Outstanding Achievement Award from Life Sciences Scotland

2018-05-17 globenewswire
EDINBURGH, United Kingdom, May 17, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today it has been honored with two prestigious awards from Life Sciences Scotland during its annual Life Sciences Awards gala event held in Glasgow on May 16, 2018. Hugh S. Griffith, Chief Executive Officer and Founder, was presented with the Outstanding Contribution award. Additionally, NuCana was awarded Investment of the Year.
NCNA

0
NCNA / NuCana plc null

2018-04-19 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,"]3(#,X/CYS=')E86T-"FC>[email protected][email protected]
NCNA

3
NCNA / NuCana plc 6-K (Current Report of Foreign Issuer)

2018-04-09 sec.gov - 3
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
NCNA

612
Stocks To Watch: Back To School For Apple

2018-03-24 seekingalpha - 1
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
TSRO AZN TWX UAA KAR WBA AMBA NRGEO NKE IMGN AVGO BOX TEAM WKHS GLW UPS STZ DDAIF TWC GME NRG NITE PVH OLBK ROKU VEEV GDDY QCOM BB LZB DCPH FB ARRS DAN TM AXL ADDYY KDNUU GPI SWKS AOS PQG AAPL LULU GM INTC JASO PAYX QRVO F SHLO RYB FDX BB RHT UA AZN KND MU NCNA ONE MRK R ADSK

0
NCNA / NuCana plc 20-F

2018-03-22 sec.gov
ncna-20f_20171231.htm As filed with the Securities and Exchange Commission on March 22, 2018 UNITED STATES
NCNA

Related Articles

REPH: Recro Pharma Analysis and Research Report

12h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

13h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

13h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 67022C106